Successful Treatment with Triple Therapy of Amphotericin B, Voriconazole and Flucytosine on an AIDS Patients with Severe Cryptococcal Meningitis

Open access


A 35-year-old man (body weight = 63 kg) with AIDS complaining fever and headache after having commenced anti-retroviral therapy (ART) for a week was admitted to our hospital. Five lumbar punctures performed during 38 days could not confirm a cryptococcal meningitis (CM) based on staining or culture methods for cerebrospinal fluid (CSF). The disease quickly progressed with serious hearing/vision impairment and frequent onset of seizure and coma after being treated with corticosteroids for five days, and then CM was confirmed. Subsequent lumbar puncture showed elevated intracranial pressure as high as 870 mm H2O, even though treated with standard antifungal regimens for CM. His disease was finally controlled by a new triple therapy with amphotericin B (0.7 mg•kg-1•day-1, intravenously), flucytosine (100 mg/kg perday, orally in four divided doses), and voriconazole (200 mg every 12 hours) and ART containing lamivudine (300 mg/day), stavuding (30 mg, twice a day) and efavirenz (300 mg, orally every night). Although it is rare, negative CSF stain or culture for cryptococci in AIDS patients with CM can persist for a long time. Corticosteroids should be used cautiously when an effective anti-fungal therapy is not administered. Triple therapy with amphotericin B, flucytosine and voriconazole may be selectively applied in severe CM. Voriconazole can be co-administered with efavirenz with modified dosing

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1 Park BJ Wannemuehler KA Marston BJ Govender N Pappas PG Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009;23:525-530.

  • 2 Perfect JR Dismukes WE Dromer F Goldman DL Graybill JR Hamill RJ et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50:291-322.

  • 3 Serena C Pastor FJ Marine M Rodríguez MM Guarro J. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother 2007;60:162-165.

  • 4 Pfaller MA Messer SA Boyken L Rice C Tendolkar S Hollis RJ et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005;43: 2163-2167.

  • 5 Liu P Foster G LaBadie RR Gutierrez MJ Sharma A. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 2008;48:73-84.

  • 6 Adam P Sobek O Dolezil D Lodin Z Kasík J Hajduková L et al. Cryptococcal meningitis--a follow-up study of a serious clinical entity: quick cytological and microbiological diagnostics using a special staining procedure in cerebrospinal fluid specimens. Folia Microbiol (Praha) 2009;54:567-568.

  • 7 Cachay ER Caperna J Sitapati AM Jafari H Kandel S Mathews WC. Utility of clinical assessment imaging and cryptococcal antigen titer to predict AIDS-related complicated forms of cryptococcal meningitis. AIDS Res Ther 2010;7:29.

  • 8 Micol R Lortholary O Sar B Laureillard D Ngeth C Dousset JP et al. Prevalence determinants of positivity and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 2007;45:555-559.

  • 9 Carbonara S Regazzi M Ciraci E Villani P Stano F Cusato M et al. Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis. Ann Pharmacother 2009;43:978-984.

  • 10 Haddow LJ Colebunders R Meintjes G Lawn SD Elliott JH Manabe YC et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010;10:791-802.

  • 11 Cinel I Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009;37:291-304.

  • 12 Russell JA Walley KR Gordon AC Cooper DJ Hébert PC Singer J et al. Interaction of vasopressin infusion corticosteroid treatment and mortality of septic shock. Crit Care Med 2009;37:811-818.

Gesamte Zeit Letztes Jahr Letzte 30 Tage
Abstract Views 0 0 0
Full Text Views 145 52 1
PDF Downloads 65 26 0